Page last updated: 2024-12-08

2-(4-methyl-1-piperazinyl)aniline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

2-(4-methyl-1-piperazinyl)aniline, also known as **N-(4-methylpiperazin-1-yl)benzenamine**, is an organic compound that has a significant role in research due to its potential as a building block for various pharmaceutical and material applications.

**Here's a breakdown of its importance:**

**1. Building Block for Pharmaceuticals:**

* **Antidepressant Activity:** This compound serves as a precursor for the synthesis of several antidepressants. Its structural similarity to known serotonin reuptake inhibitors (SSRIs) makes it a promising starting point for developing new antidepressant therapies.
* **Anticancer Activity:** Research suggests that derivatives of this compound may exhibit anticancer activity. This is due to their ability to interact with specific cellular targets involved in cancer cell growth and proliferation.
* **Other Therapeutic Applications:** 2-(4-methyl-1-piperazinyl)aniline can be used as a starting point for synthesizing compounds with diverse pharmacological activities, including antihistamines, anti-inflammatory agents, and antipsychotics.

**2. Materials Science:**

* **Organic Electronics:** This compound can be used as a building block for organic semiconductors, which are key components of organic light-emitting diodes (OLEDs), solar cells, and other organic electronic devices.
* **Polymer Synthesis:** Derivatives of 2-(4-methyl-1-piperazinyl)aniline can be incorporated into polymers to enhance their conductivity, optical properties, and mechanical strength. This opens up possibilities for developing new materials with specific functionalities.

**3. Research Tool:**

* **Chemical Synthesis:** It serves as a versatile reagent in organic synthesis, allowing for the creation of new molecules with diverse properties. Its reactivity and functional groups make it suitable for a wide range of reactions.
* **Biological Research:** 2-(4-methyl-1-piperazinyl)aniline can be used as a probe to study biological systems and processes. For instance, its derivatives can be labelled with radioactive isotopes or fluorescent tags to track their distribution and interaction with specific biological targets.

**Overall, 2-(4-methyl-1-piperazinyl)aniline is a versatile compound with vast potential in research. Its unique chemical structure and reactivity make it an invaluable tool for developing new pharmaceuticals, materials, and understanding biological processes.**

**It's important to note that the specific applications and research interests related to this compound can vary significantly.** If you're interested in learning more about its specific uses in a particular field, you should consult specialized scientific literature and databases.

Cross-References

ID SourceID
PubMed CID286547
CHEMBL ID1879790
CHEBI ID113157
SCHEMBL ID1926749

Synonyms (43)

Synonym
AC-3593
180605-36-1
smr000121448
MLS000528973
EN300-11843
BB 0245145
2-(4-methyl-1-piperazinyl)aniline
nsc145003
nsc-145003
2-(4-methyl-piperazin-1-yl)-phenylamine
STK141998
2-(4-methylpiperazin-1-yl)aniline
CHEBI:113157
AKOS000103050
chembl1879790 ,
bdbm50097721
A835370
A4002
1-(2-aminophenyl)-4-methylpiperazine
2-(4-methyl-1-piperazinyl)-benzenamine
HMS2318E12
AM803393
FT-0643742
2-(4-methylpiperazino)aniline
CL1602
mfcd04035359
SY007572
SCHEMBL1926749
PS-5147
2-(4-methylpiperazin-1-yl)-aniline
INWHDRNGZMHXEZ-UHFFFAOYSA-N
W-206285
M2592
Q27193623
2-(4-methylpiperazin-1-yl)aniline, aldrichcpr
benzenamine, 2-(4-methyl-1-piperazinyl)-
DTXSID60301626
Z57625083
CS-W003132
F1911-3703
QSS ,
2-(4-methylpiperazine)aniline
6-amino-3,4-dihydro-2h-pyrido[2,3-e][1,2,4]thiadiazine-7-sulfonamide 1,1-dioxide
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
piperazines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLS proteinHomo sapiens (human)Potency31.62280.35487.935539.8107AID624170
gemininHomo sapiens (human)Potency25.92900.004611.374133.4983AID624296
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Alpha-2C adrenergic receptorHomo sapiens (human)Ki0.23990.00030.483410.0000AID1232265
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (14)

Processvia Protein(s)Taxonomy
regulation of smooth muscle contractionAlpha-2C adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2C adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2C adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2C adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2C adrenergic receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
alpha2-adrenergic receptor activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2C adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingAlpha-2C adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2C adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2C adrenergic receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
cytoplasmAlpha-2C adrenergic receptorHomo sapiens (human)
endosomeAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1232269Antagonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as inhibition of UK14304-induced cytoplasmic calcium mobilization at 20 uM preincubated for 15 mins by fluorometric analysis relative2015Bioorganic & medicinal chemistry, Jul-15, Volume: 23, Issue:14
Cell-based and virtual fragment screening for adrenergic α2C receptor agonists.
AID1232265Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis2015Bioorganic & medicinal chemistry, Jul-15, Volume: 23, Issue:14
Cell-based and virtual fragment screening for adrenergic α2C receptor agonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.53 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]